



国内版

国际版

Real-World Experience with Tofacitinib for the Treatment of Ulcerative Colitis: A Re



All

Images

Videos

翻译成中文

关闭取词

59,800 Results

Any time ▾

Tofacitinib in the treatment of ulcerative colitis ...

<https://journals.sagepub.com/doi/full/10.1177/1756284819848631>

Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate–severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data.

Author: Ferdinando D'Amico, Tommaso Loren... Publish Year: 2019

Tofacitinib in the treatment of ulcerative colitis ...

<https://journals.sagepub.com/doi/epub/10.1177/1756284819848631>

Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate–severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data.

Tofacitinib for the treatment of ulcerative colitis ...

<https://www.tandfonline.com/doi/abs/10.1080/1744666X.2018.1532291>

Expert commentary: Tofacitinib will be the first drug on the class of JAK inhibitors to be available for treatment of ulcerative colitis. The efficacy of the drug, with a rapid onset of action even in cases of severe colitis, oral administration, and possibility to use the drug intermittently without generating immunogenicity, will bring about a redesign of current treatment paradigms for ulcerative colitis.

Cited by: 2 Author: Agnès Fernández-Clotet, Jesús Castro-P...

Publish Year: 2018

Safety of Tofacitinib for Treatment of Ulcerative Colitis ...

[https://www.cghjournal.org/article/S1542-3565\(18\)31278-3/fulltext](https://www.cghjournal.org/article/S1542-3565(18)31278-3/fulltext)

Tofacitinib is an oral, small molecule Janus kinase inhibitor approved in several countries for the treatment of ulcerative colitis (UC). In 2 identical phase 3, placebo-controlled, 8-week UC induction studies, 1 x 1 Sandborn, W.J., Su, C., Sands, B.E. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis.

Cited by: 5 Author: William J. Sandborn, Julián Panés, Geert...

Publish Year: 2018

Tofacitinib for the treatment of ulcerative colitis

https://www.researchgate.net/publication/328084935_Tofacitinib_for_the_treatment_of...

Lichtenstein GR et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study. Am J Gastroenterol, 2017;112(S1). [Abstract 714].

Name of journal: World Journal of Meta-Analysis (WJMA)

Manuscript Type: Review

Tofacitinib for the Treatment of Ulcerative Colitis

Jessica Rosenberg MD, Joshua M. Steinberg MD, Mark C. Mattar MD

Abstract: Ulcerative colitis (UC) is a chronic immune-mediated inflammatory condition affecting the colon. Recently, tofacitinib, an oral small molecule that is an inhibitor of the Janus kinase (JAK) signal transduction pathway, was proven efficacious for inducing and maintaining remission in adult patients with moderate to severe UC in three global Phase III studies. The purpose of this review is to summarize existing data on the efficacy, safety, and quality of life issues related to use tofacitinib as well as highlight recent real-world experience with this drug among patients with ulcerative colitis.

INTRODUCTION

Ulcerative colitis (UC) is a chronic inflammatory condition that primarily affects the colon,

Match Overview

1	Internet 110 words crawled on 10-Apr-2019 www.ncbi.nlm.nih.gov	3%
2	Internet 108 words crawled on 26-Jan-2018 www.nejm.org	3%
3	Crossref 76 words Nadia Griller, Lawrence Cohen. "Rapid Onset of Tofacitinib Induction Therapy for the Treatment of Ulcerative Coliti	2%
4	Crossref 75 words Freddy Caldera, Mary S Hayney, Raymond K Cross. "Usi ng Number Needed to Harm to Put the Risk of Herpes ...	2%
5	Crossref 65 words Catherine Le Berre, Damien Loeuille, Laurent Peyrin-Bir oulet. "Combination therapy with vedolizumab and tofa ...	2%
6	Crossref 58 words Jeffrey A. Berinstein, Calen A. Steiner, Randolph E. Rega I, John I. Allen et al. "Efficacy of Induction Therapy With Hi	2%
7	Crossref 57 words William J. Sandborn, Julián Panés, Geert R. D'Haens, B ruce E. Sands et al. "Safety of Tofacitinib for Treatment of	2%
8	Crossref 44 words Bruce E. Sands, Pam R. Taub, Alessandro Armuzzi, Gary S. Friedman et al. "Tofacitinib Treatment Is Associated W	1%
9	Internet 44 words crawled on 02-Aug-2019 www.dovepress.com	1%
10	Crossref 43 words Stephen Hanauer, Remo Panaccione, Silvio Danese, Ad am Cheifetz et al. "Tofacitinib Induction Therapy Reduc ...	1%
11	Crossref 35 words S. Singh, M. Fumery, W. J. Sandborn, M. H. Murad. "Syste	1%



国内版

国际版

Tofacitinib for the treatment of ulcerative colitis: A review of the literature



All

Images

Videos

翻译成中文

关闭取词

518,000 Results

Any time ▾

[PDF] Tofacitinib for induction of remission in ulcerative ...

www.annalsgastro.gr/files/journals/1/earlyview/2018/ev-05-2018-07-AG3986-0276.pdf

Conclusion In patients with moderate-to-severe ulcerative colitis, short-term treatment with tofacitinib is effective for induction of remission and improvement of quality of life. Keywords Tofacitinib, ulcerative colitis, meta-analysis

Promising biological therapies for ulcerative colitis: A ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644886>

Nov 15, 2015 · Core tip: Ulcerative colitis (UC) is a chronic lifelong condition characterized by alternating flare-ups and remission. Current treatment modalities for UC include 5-aminosalicylates, corticosteroids, immunosuppressants (e.g., cyclosporine, tacrolimus), and surgery. Medical treatment aims to induce remission and prevent relapse of disease activity.

Published in: World Journal of Gastrointestinal Pathophysiology · 2015

Authors: Hirotada Akiho · Azusa Yokoyama · Shuichi Abe · Yuichi Nakazono · Masatoshi Mura...

About: Text mining · Bioinformatics

Tofacitinib for the treatment of ulcerative colitis ...

<https://www.tandfonline.com/doi/abs/10.1080/1744666X.2018.1532291>

Expert commentary: Tofacitinib will be the first drug on the class of JAK inhibitors to be available for treatment of ulcerative colitis. The efficacy of the drug, with a rapid onset of action even in cases of severe colitis, oral administration, and possibility to use the drug intermittently without generating immunogenicity, will bring about a redesign of current treatment paradigms for ulcerative colitis.

Cited by: 6 Author: Agnès Fernández-Clotet, Jesús Castro-P...

Publish Year: 2018

(PDF) Tofacitinib for induction of remission in ulcerative ...

https://www.researchgate.net/publication/325095720_Tofacitinib_for_induction_of...

Conclusion In patients with moderate-to-severe ulcerative colitis, short-term treatment with tofacitinib is effective for induction of remission and improvement of quality of life.